ABOUT IDT BIOLOGIKA
With passion we bring pharmaceutical solutions to life
IDT Biologika, part of SK bioscience, is a global CDMO providing end-to-end solutions for cell-culture and microbial-based proteins, vaccines, gene and immune therapeutics, biosimilars, monoclonal antibodies and sterile injectables.
With more than 100 years of biopharmaceutical experience, we partner with pharmaceutical and biotech companies throughout the entire product lifecycle—from development and technology transfer to clinical and commercial manufacturing.
Our integrated service offering includes process and analytical development, drug substance manufacturing, aseptic fill-finish, secondary packaging, and quality control. Combining flexibility, operational excellence, and regulatory expertise, we help accelerate product development and market readiness.
Leveraging proprietary technologies, including in-house cell lines, and the expertise of highly experienced teams, we enable seamless technology transfer, efficient scale-up, and reliable manufacturing for clinical and commercial programs
VIDEOS
FEATURED PRESENTATIONS
CONTACT INFORMATION
IDT Biologika
Dessau-Rosslau, Germany
US Sales Office, USA
Phone: +49 (0) 162 1009526
Contact: Angelika Rublack, IDT Biologika
BROCHURES AND SERVICES
ARTICLES
NEWS
- IDT Biologika Appoints Federico Pollano As New Chief Commercial Officer
- IDT Biologika Receives CDMO Leadership Awards 2024 In Six Categories
- IDT Biologika Collaborates With CanVirex To Push Forward The Treatment Of Cancer
- IDT Biologika Receives CDMO Leadership Awards 2023 in Five Categories
- IDT Biologika With New Dual Leadership: Dr. Ulrich Valley Appointed Second Managing Director
- IDT Biologika Receives CMO Leadership Awards 2022 In Six Categories
- IDT Biologika Is Increasing Its Production Capacity Of Vaccines, Saxony-Anhalt's Prime Minister Reiner Haseloff Visited The New Facilities
- Valneva And IDT Biologika Announce Collaboration For Production Of Inactivated COVID-19 Vaccine VLA2001
- IDT Biologika And Takeda Support Production Of The Johnson & Johnson Single-Shot COVID-19 Vaccine
- IDT Biologika To Receive Funding For The Clinical Trials Of Phases I To III And The Application For COVID-19 Vaccine Approval
- SARS-CoV-2: IDT Biologika Fills Vaccine Candidate - Clinical Phase About To Begin